| Literature DB >> 18254958 |
Hui Ye1, Tianwei Yu, Stephane Temam, Barry L Ziober, Jianguang Wang, Joel L Schwartz, Li Mao, David T Wong, Xiaofeng Zhou.
Abstract
BACKGROUND: The head and neck/oral squamous cell carcinoma (HNOSCC) is a diverse group of cancers, which develop from many different anatomic sites and are associated with different risk factors and genetic characteristics. The oral tongue squamous cell carcinoma (OTSCC) is one of the most common types of HNOSCC. It is significantly more aggressive than other forms of HNOSCC, in terms of local invasion and spread. In this study, we aim to identify specific transcriptomic signatures that associated with OTSCC.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18254958 PMCID: PMC2262071 DOI: 10.1186/1471-2164-9-69
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Principle component analysis. Global gene expression profiles on 53 OTSCC and 22 matching normal samples were obtained as described in Materials and Methods section. Principle Component (PC) analysis was performed based on the expression profiles of samples. The first 3 PCs were plotted. Red: OTSCC, Blue: normal.
Signature gene sets for OTSCC
| MMP1 | 204475_at | matrix metalloproteinase 1 | 11q22.3 | |
| MMP10 | 205680_at | matrix metalloproteinase 10 | 11q22.3 | |
| MMP3 | 205828_at | matrix metalloproteinase 3 | 11q22.3 | |
| MMP12 | 204580_at | matrix metallopeptidase 12 | 11q22.3 | |
| PTHLH | 211756_at | parathyroid hormone-like hormone | 12p12.1-p11.2 | |
| INHBA | 210511_s_at | inhibin, beta A | 7p15-p13 | |
| LAMC2 | 202267_at | laminin, gamma 2 | 1q25-q31 | |
| IL8 | 202859_x_at | interleukin 8 | 4q13-q21 | |
| KRT17 | 205157_s_at | keratin 17 | 17q12-q21 | |
| COL1A2 | 202404_s_at | collagen, type I, alpha 2 | 7q22.1 | |
| IFI6 | 204415_at | interferon, alpha-inducible protein 6 | 1p35 | |
| ISG15 | 205483_s_at | ISG15 ubiquitin-like modifier | 1p36.33 | |
| PLAU | 205479_s_at | plasminogen activator, urokinase | 10q24 | |
| GREM1 | 218468_s_at | gremlin 1 | 15q13-q15 | |
| MMP9 | 203936_s_at | matrix metallopeptidase 9 | 20q11.2-q13.1 | |
| IFI44 | 214453_s_at | interferon-induced protein 44 | 1p31.1 | |
| CXCL1 | 204470_at | chemokine (C-X-C motif) ligand 1 | 4q21 | |
| KRT4 | 213240_s_at | keratin 4 | 12q12-q13 | |
| MAL | 204777_s_at | mal, T-cell differentiation protein | 2cen-q13 | |
| CRNN | 220090_at | Cornulin | 1q21 | |
| SCEL | 206884_s_at | Sciellin | 13q22 | |
| CRISP3 | 207802_at | cysteine-rich secretory protein 3 | 6p12.3 | |
| SPINK5 | 205185_at | serine protease inhibitor, Kazal type 5 | 5q32 | |
| CLCA4 | 220026_at | chloride channel, calcium activated, family member 4 | 1p31-p22 | |
| ADH1B | 209612_s_at 209613_s_at | alcohol dehydrogenase IB (class I), beta polypeptide | 4q21-q23 | |
| P11 | 206605_at | 26 serine protease | 12q13.1 | |
| TGM3 | 206004_at | transglutaminase 3 | 20q11.2 | |
| RHCG | 219554_at | Rhesus blood group, C glycoprotein | 15q25 | |
| PPP1R3C | 204284_at | protein phosphatase 1, regulatory (inhibitor) subunit 3C | 10q23-q24 | |
| CEACAM7 | 206199_at | carcinoembryonic antigen-related cell adhesion molecule 7 | 19q13.2 | |
| HPGD | 203914_x_at | hydroxyprostaglandin dehydrogenase 15-(NAD) | 4q34-q35 | |
| CFD | 205382_s_at | D component of complement (adipsin) | 19p13.3 | |
| ABCA8 | 204719_at | ATP-binding cassette, sub-family A (ABC1), member 8 | 17q24 | |
| CLU | 222043_at | Clusterin | 8p21-p12 | |
| CYP3A5 | 214235_at | cytochrome P450, family 3, subfamily A, polypeptide 5 | 7q21.1 | |
* The complete lists of upregulated and downregulated transcripts in OTSCCs were presented in Supplement Table S1 and S2, respectively.
Figure 2Classification of OTSCC and matching normal using global gene expression analysis. A signature gene set of 35 genes was created based on RMA analysis of the expression profiles on 53 OTSCC and 22 matching normal samples. Hierarchical clustering was performed based on this signature gene set. To removed the effect of baseline and scale in the color image, the data from every transcript was standardized (remove mean, divide by standard deviation) before plotting.
Selected biological processes that altered in OTSCCs *
| Collagen catabolism | GO:0030574 | 38.9 | 2.7 E-09 |
| Positive regulation of chemotaxis | GO:0050921 | 33.3 | 0.0029 |
| Phosphate transport | GO:0006817 | 21.7 | 1.5 E-12 |
| Extracellular matrix organization and biogenesis | GO:0030198 | 12.9 | 0.00089 |
| Positive regulation of I-kappaB kinase/NF-kappaB cascade | GO:0043123 | 8.8 | 0.00038 |
| Superoxide release | GO:0042554 | 40.0 | 0.0015 |
| Keratinization | GO:0031424 | 33.3 | 1.1 E-05 |
| Hydrogen peroxide metabolism | GO:0042743 | 25.0 | 0.0042 |
| Response to hydrogen peroxide | GO:0042542 | 22.2 | 0.0053 |
| Keratinocyte differentiation | GO:0030216 | 21.1 | 8.0 E-05 |
* The complete lists of enhanced and suppressed biological processes (BP), molecular functions (MF) and cellular components (CC) in OTSCCs were presented in Supplement Table S3 and S4, respectively.
** The percent of genes exhibiting expressional changes among all genes that constitutes a specific GO entity.
Figure 3Expression values of the genes constitute of the altered biological processes in OTSCC. The altered biological processes in OTSCC were identified by Gene Ontology analysis (Table 2) as described in the Materials and Methods section. The expression values of the genes consisting of the altered biological processes were extracted from the RMA based expression index, and individual heat maps were generated for the identified altered biological processes in OTSCC. To removed the effect of baseline and scale in the color image, the data from every transcript was standardized (remove mean, divide by standard deviation) before plotting. To increase the contrast, values lower than the 10th percentile were replaced with the 10th percentile, and values higher than the 95th percentile were replaced with the 95th percentile.
Expression values of genes that constitute the collagen catabolism (GO:0030574) and positive regulation of chemotaxis (GO:0050921) processes in OTSCC.
| 4313 | MMP2 | 1.44 | 0.109 | |
| 4317 | MMP8 | 1.01 | 0.7963 | |
| 4325 | MMP16 | 0.93 | 0.1117 | |
| 4327 | MMP19 | 1.08 | 0.4404 | |
| 5184 | PEPD | 0.92 | 0.4602 | |
| 5645 | PRSS2 | 0.76 | 0.0187 | |
| 5653 | KLK6 | 0.73 | 0.4218 | |
| 5657 | PRTN3 | 0.96 | 0.2656 | |
| 9508 | ADAMTS3 | 1.05 | 0.5858 | |
| 9509 | ADAMTS2 | 1.19 | 0.2451 | |
| 56547 | MMP26 | 0.94 | 0.2394 | |
| 9353 | SLIT2 | 0.88 | 0.1700 | |
| 566 | AZU1 | 0.95 | 0.1643 | |
| 7422 | VEGF | 1.20 | 0.4614 | |
| 7857 | SCG2 | 1.00 | 0.9901 |
Figure 4Elevated expressions of IL8 and MMP9 genes in OTSCC. The qRT-PCR tests were performed with primer sets specific for IL8 gene (A) and MMP9 gene (B) on 25 OTSCC cases and 12 normal matching samples. The p values (Wilcoxon test) were presented. Immunohistochemistry tests were performed using monoclonal antibody to IL8 and MMP9 and detected using peroxidase-antiperoxidase and diaminebenzadine (DAB) on 10 OTSCC cases. Positive stained SCC cells were observed in 4 cases for IL8 and 8 cases for MMP9. Representative images for IL8 (C) and MMP9 (D) were presented.
Clinical Characterization of the OTSCC Patients*
| OTSCC (n = 53) | Normal (n = 22) | ||
| Average | 57 | 56 | |
| (Range) | 32–82 | 37–78 | |
| Male (%) | 73.6 | 59.1 | |
| Female (%) | 26.4 | 40.9 | |
| Tongue (%) | 100 | 100 | |
| Stage 4 (%) | 56.6 | ||
| Stage 3 (%) | 7.5 | ||
| Stage 2 (%) | 22.6 | ||
| Stage 1 (%) | 13.2 | ||
| Stage 2 (%) | 43.4 | ||
| Stage 1 (%) | 7.5 | ||
| Stage 0 (%) | 49.1 |
* The M stage data is not available.